Moderna, Inc.

NasdaqGS MRNA

Moderna, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 65.90%

Moderna, Inc. Gross Profit Margin is 65.90% for the Trailing 12 Months (TTM) ending September 30, 2024, a 74.78% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Moderna, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 37.70%, a -51.95% change year over year.
Moderna, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 78.48%, a -7.47% change year over year.
Moderna, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 84.81%, a 107.01% change year over year.
Moderna, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -1,209.47%, a -85.45% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGS: MRNA

Moderna, Inc.

CEO	Mr. Stephane Bancel
IPO Date	Dec. 7, 2018
Location	United States
Headquarters	200 Technology Square
Employees	5,600
Sector	Health Care
Industries Biotechnology Pharmaceuticals Vaccines

Description

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years